Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.6 USD | +1.42% | +13.68% | -22.60% |
04-15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
03-25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.60% | 2.28B | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Wedbush Cuts Price Target on Intellia Therapeutics to $58 From $68, After Q2 Report, Allo-NTLA-5001 Development Update; Neutral Rating Kept